Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Nature genetics - 1 Dec 2009

Ross Colin J D, Katzov-Eckert Hagit, Dubé Marie-Pierre, Brooks Beth, Rassekh S Rod, Barhdadi Amina, Feroz-Zada Yassamin, Visscher Henk, Brown Andrew M K, Rieder Michael J, Rogers Paul C, Phillips Michael S, Carleton Bruce C, Hayden Michael R

Abstract excerpt

Cisplatin is a widely used and effective chemotherapeutic agent, although its use is restricted by the high incidence of irreversible ototoxicity associated with it. In children, cisplatin ototoxicity is a serious and pervasive problem, affecting more than 60% of those receiving cisplatin and com...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Catechol O-Methyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Cohort Studies

Share to Genetic Variation

Share to Hearing Loss

Share to Methyltransferases

Source

Identifiers

PMID: 19898482
DOI: 10.1038/ng.478

Genes

COMT
TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19898482-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.PMID 19898482Read ↗

Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.Semantic proximity Read ↗

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.Semantic proximity Read ↗

Pharmacogenomics of cisplatin-induced ototoxicity.Semantic proximity Read ↗

TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.Semantic proximity Read ↗

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.Semantic proximity Read ↗

Challenges in interpreting the evidence for genetic predictors of ototoxicity.Semantic proximity Read ↗

Genetic variants associated with cisplatin-induced ototoxicity.Semantic proximity Read ↗

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.Semantic proximity Read ↗

Otoprotection in Children Treated for Cancer: A CODEPEH Review Using PRISMA Methodology on Pharmacological Agents, Biomarkers and Genetic SusceptibilitySemantic proximity Read ↗

Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.Semantic proximity Read ↗

Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.Semantic proximity Read ↗

SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.